An interventional study of WeCan-Rural Program in Breast Cancer Survivorship, Weight Management and Cardiovascular (CV) Risk, sponsored by Duke University. Recruiting at 5 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Duke University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Breast Neoplasms by Duke University — 8 open to participants now, 10 under way, none of them phase 3. Breast Neoplasms · Duke University.
Among the 69 studies in Breast Neoplasms by Duke University, this one is the 27th largest by planned enrollment of the 58 interventional ones that give a count, is one of 7 that started in 2026, is one of 39 with no phase, and was the 67th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →8 of the 69 studies in Breast Neoplasms by Duke University are open now, in 1 country. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18–50 · Women only
Duke University · Sites in United States
Ages 18+ · Women only
Duke University · Sites in United States
Ages 21–90 · Women only
Duke University · Sites in United States
Ages 18+ · Women only
Duke University · Sites in United States
Ages 18–39
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 13
First in 1997; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 40 across the 58 interventional studies, 61 across the 10 observational. Of the 55 that completed or were terminated, 12 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
3 of the studies in Breast Neoplasms by Duke University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07426952Duke UniversityWeight Management After Cancer for Survivors in Rural Communities | 2026-12-31 |
| NCT06983691Duke UniversityPatient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib | 2027-03 |
| NCT06658912Duke UniversityPlanning Grant for TOPS for Breast Cancer Survivors | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 69 studies in Breast Neoplasms by Duke University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is testing a new program called WeCan-Rural, designed to help breast cancer survivors manage symptoms and build healthy habits like eating well, staying active, and managing their weight. These changes may help lower the risk of heart disease after cancer treatment.
The study will answer two main questions:
Here's what participants will do:
Breast cancer survivors often face long-term health challenges after treatment, including a higher risk of heart disease. This risk is especially high for women living in rural areas, where access to healthcare and healthy food may be limited, and opportunities for physical activity may be harder to find. Many survivors also deal with ongoing symptoms like pain, fatigue, and emotional distress, which can make it harder to eat well, stay active, and manage their weight.
This study will test a program called WeCan-Rural, designed to help breast cancer survivors improve their health and lower their risk of heart disease. The program teaches skills for healthy eating, physical activity, and managing symptoms that can get in the way of a healthy lifestyle. It includes 12 weekly sessions delivered remotely through Zoom, so participants can join from home. Each session lasts about an hour and covers topics like nutrition, exercise, and ways to cope with symptoms using strategies like relaxation and pacing.
Participants will receive tools to help them track their progress, including a wireless activity tracker, a scale, and a blood pressure monitor. They'll also get printed materials and access to online videos showing how to do recommended exercises. If needed, participants will be provided with a tablet and data plan to make sure they can join the sessions.
The study will include 40 breast cancer survivors who have completed treatment and are living in rural, medically underserved areas. Half will receive the WeCan-Rural program, and half will receive standard health information from the National Cancer Institute. Researchers will look at how easy it is to recruit and keep participants in the program, how satisfied participants are with it, and whether it helps improve the participant's weight, symptoms, diet, physical activity, and confidence in managing the participant's health. The study will also measure changes in heart health indicators like blood pressure, cholesterol, and blood sugar.
If the program is found to be helpful and well-received, it may be tested in a larger study in the future.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive the WeCan-Rural intervention, which includes twelve sessions delivered remotely (i.e., videoconferencing) by a trained therapist.
Behavioral: WeCan-Rural Program
Participants will receive the National Cancer Institute-developed booklet "Facing Forward: Life After Cancer Treatment," which presents information about cancer survivorship topics.
The WeCan-Rural program includes 12, one-hour weekly sessions via Zoom that help breast cancer survivors manage symptoms like pain, fatigue, and emotional distress, while also building healthy habits around eating, exercise, and weight management.
Satisfaction with Treatment and Interventionist as measured by the Satisfaction with Therapy and Therapist Scale-Revised (STTS-R)
Participants will complete the 13-item Satisfaction with Therapy and Therapist Scale-Revised specific to the program they received. The first 12 items ask participants to rate their agreement with statements related to intervention satisfaction on a 5-point scale ranging from "strongly disagree" (1) to "strongly agree" (5). The 13th item asks "How much did the intervention help with your symptoms?" with 5 answer choices ranging from "made things a lot better" to "made things a lot worse."
Time frame: Post-treatment (about 12-14 weeks after baseline)
Acceptability as measured by the Treatment Acceptability Questionnaire
The Treatment Acceptability Questionnaire is a six-item scale assessing participants' views of an intervention as acceptable, ethical, and effective. Items are rated on a 7-point Likert scale (e.g., 1 "very unacceptable" to 7 "very acceptable") and averaged.
Time frame: Post-treatment (about 12-14 weeks after baseline)
Change in blood pressure (systolic and diastolic)
Both systolic and diastolic blood pressure will be assessed at the baseline and follow-up assessment.
Time frame: From Baseline to Post-treatment (about 12-14 weeks after baseline)
Change in weight
Participants will be weighed at each assessment.
Time frame: From Baseline to Post-treatment (about 12-14 weeks after baseline)
Change in total cholesterol
Cholesterol will be assessed through peripheral blood at the baseline and follow-up assessment.
Time frame: From Baseline to Post-treatment (about 12-14 weeks after baseline)
Change in LDL cholesterol
LDL cholesterol will be assessed through peripheral blood at the baseline and follow-up assessment.
Time frame: From Baseline to Post-treatment (about 12-14 weeks after baseline)
Change in HDL cholesterol
HDL cholesterol will be assessed through peripheral blood at the baseline and follow-up assessment.
Time frame: From Baseline to Post-treatment (about 12-14 weeks after baseline)
Change in hemoglobin A1c
Hemoglobin A1c will be assessed through peripheral blood at the baseline and follow-up assessment.
Time frame: From Baseline to Post-treatment (about 12-14 weeks after baseline)
Change in C-reactive protein
C-reactive protein will be assessed through peripheral blood at the baseline and follow-up assessment.
Time frame: From Baseline to Post-treatment (about 12-14 weeks after baseline)
Change in high sensitivity troponin
High sensitivity troponin will be assessed through peripheral blood at the baseline and follow-up assessment.
Time frame: From Baseline to Post-treatment (about 12-14 weeks after baseline)
Change in aerobic capacity and endurance as measured by the 6-Minute Walk Test
The 6-minute walk test is a self-paced, timed test of the total distance in meters that a patient is able to walk over a six-minute period and assesses the ability to exert effort during activity. Higher values indicate higher aerobic capacity and endurance.
Time frame: From Baseline to Post-treatment (about 12-14 weeks after baseline)
Pain severity and interference as measured by the Brief Pain Inventory
The Brief Pain Inventory will be used to assess pain severity and interference from pain across important life domains (e.g., general activity, work, relations with others). This measures includes a body map on which the patient can mark the location(s) in which they are experiencing pain, as well as 8 questions on a scale of 0 to 10 with higher scores indicating worse pain severity or pain interference.
Time frame: Baseline, Post-treatment (about 12-14 weeks after baseline)
Emotional distress as measured by PROMIS Depression Short Form
Depressive symptoms will be assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Depression Short Form, an 8-item measure assessing symptoms of depression in the last week. Responses are on a 5-point scale from "never" (1) to "always" (5).
Time frame: Baseline, Post-treatment (about 12-14 weeks after baseline)
Emotional distress as measured by PROMIS Anxiety Short Form
Symptoms of Anxiety will be assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Short Form, an 8-item measure assessing symptoms of anxiety in the last week. Responses are on a 5-point scale from "never" (1) to "always" (5).
Time frame: Baseline, Post-treatment (about 12-14 weeks after baseline)
Fatigue as measured by PROMIS Fatigue Scale
Fatigue will be assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Scale, a 6-item self-report measure of fatigue. Participants are asked to think about the last week when responding to each item (e.g., "In the past 7 days, how run-down did you feel, on average?"), providing ratings on a scale from "not at all" (1) to "very much" (5).
Time frame: Baseline, Post-treatment (about 12-14 weeks after baseline)
Diet as measured by the Dietary Screener Questionnaire
The Dietary Screener Questionnaire is a 25-item measure asking participants to rate on the frequency of eating/drinking certain foods in the last week.
Time frame: Baseline, Post-treatment (about 12-14 weeks after baseline)
Eating behavior as measured by the Three Factor Eating Questionnaire
Eating behaviors will be assessed using the Three Factor Eating Questionnaire (TFEQ). The 21-item short-form will be used for the present study. The TFEQ measures three domains of eating behavior: 1) cognitive restraint, 2) uncontrolled eating, and 3) emotional eating.
Time frame: Baseline, Post-treatment (about 12-14 weeks after baseline)
Physical activity as measured by the Stanford Leisure-Time Activity Categorical Item (L-Cat)
The L-Cat is a measure of physical activity. Individuals identify which descriptive category best describes their level of activity during leisure time in the last month. Descriptive categories range from inactive to very active.
Time frame: Baseline, Post-treatment (about 12-14 weeks after baseline)
Patient self-efficacy for chronic disease coping as measured by Self-Efficacy for Managing Chronic Illness Scale
The 6-item Self-Efficacy for Managing Chronic Illness Scale will be used to assess participants' current confidence in their ability to prevent symptoms (e.g., pain, fatigue, distress) from interfering with life. Responses are on a 10-point scale from "not at all confident" (1) to "totally confident" (10).
Time frame: Baseline, Post-treatment (about 12-14 weeks after baseline)
Patient self-efficacy for managing chronic conditions as measured by the PROMIS Self-Efficacy for Managing Symptoms Short Form
The 4-item PROMIS Self-Efficacy for Managing Symptoms will be used to assess participants' confidence in their ability to manage symptoms (e.g. during daily activities, in a public place). Items are scored on a 5-point Likert scale, with higher scores indicating greater confidence.
Time frame: Baseline, Post-treatment (about 12-14 weeks after baseline)
Weight-related self-efficacy as measured by the Weight Efficacy Lifestyle Questionnaire
The Weight Efficacy Lifestyle Questionnaire is an 8-item measure of eating self-efficacy. Participants are asked to provide information about how certain they are that they can resist overeating in difficult situation (e.g., over the weekend, when tired, etc.). Response choices range from 0= "not at all confident" to 10= "very confident."
Time frame: Baseline, Post-treatment (about 12-14 weeks after baseline)
Food environment as measured by the Perceived Nutrition Environment Measure
The Perceived Nutrition Environment Measure includes 53 core items to assess three types of perceived nutrition environments: community nutrition environment, consumer nutrition environment, and home food environment.
Time frame: Baseline
Assessment of rurality as measured by selected items from the Rural Active Living Perceived Support Scale
Time frame: Baseline
Health literacy as measured by Medical Term Recognition Test (METER)
The METER will be used to assess health literacy. Participants are asked to review a list of 40 words and check off those that they recognize as actual words, yielding a total score from 0 to 40. 0-20 points: Low health literacy; 21-34 points: Marginal health literacy; 35-40 points: Adequate health literacy
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 4 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.